Hyperlipidemia - Pipeline Review, H2 2015 Summary Global Markets Directs, Hyperlipidemia - Pipeline Review, H2 2015, provides an overview of the Hyperlipidemias therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set... Research Beam Model: Research Beam Product ID: 350881 2000 USD New
Hyperlipidemia - Pipeline Review, H2 2015
 
 

Hyperlipidemia - Pipeline Review, H2 2015

  • Category : Healthcare
  • Published On : September   2015
  • Pages : 128
  • Publisher : Global Markets Direct
 
 
 
Hyperlipidemia - Pipeline Review, H2 2015

Summary

Global Markets Directs, Hyperlipidemia - Pipeline Review, H2 2015, provides an overview of the Hyperlipidemias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperlipidemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperlipidemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Hyperlipidemia Overview 10
Therapeutics Development 11
Pipeline Products for Hyperlipidemia - Overview 11
Pipeline Products for Hyperlipidemia - Comparative Analysis 12
Hyperlipidemia - Therapeutics under Development by Companies 13
Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes 15
Hyperlipidemia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Hyperlipidemia - Products under Development by Companies 20
Hyperlipidemia - Products under Investigation by Universities/Institutes 22
Hyperlipidemia - Companies Involved in Therapeutics Development 23
Ahn-Gook Pharmaceutical Co., Ltd. 23
Alnylam Pharmaceuticals, Inc. 24
Amgen Inc. 25
BCWorld Pharm Co. Ltd. 26
Catabasis Pharmaceuticals, Inc. 27
CJ CheilJedang Corp. 28
Daewoong Pharmaceutical Co., Ltd. 29
HanAll Biopharma Co., Ltd. 30
Huons Co., Ltd. 31
Hyundai Pharmaceutical Co., Ltd. 32
Innovent Biologics, Inc. 33
Isis Pharmaceuticals, Inc. 34
Jeil Pharmaceutical Co., Ltd. 35
LG Life Sciences, Ltd. 36
Lotus Pharmaceutical Co., Ltd. 37
Pfizer Inc. 38
Pharmena SA 39
Prometheon Pharma, LLC 40
Protalix BioTherapeutics, Inc. 41
TSH Biopharm Corporation Limited 42
Yuhan Corporation 43
Hyperlipidemia - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
(atorvastatin calcium + losartan potassium) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
(candesartan + rosuvastatin) - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
(gemigliptin + rosuvastatin calcium) - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
(rosuvastatin calcium + metformin SR) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AEM-28-02 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
AEM-2814 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
AGSAA-010 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ALN-ANG - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
BCWPC-001 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
bococizumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BSN-272 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CAT-2000 Series - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CAT-2003 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
DWJ-1330 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DWJ-1351 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
etanercept biosimilar - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
evolocumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
HOB-071 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
HU-012 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
IBI-306 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ISIS-ANGPTL3LRx - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ISIS-ANGPTL3Rx - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
JLP-1302 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
JLP-1401 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
microRNA-30c for Hyperlipidemia and Atherosclerosis - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
N-11 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PF-06427878 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
S-0101870 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecule for Hyperlipidemia - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TRIA-662 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
YH-22189 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Hyperlipidemia - Recent Pipeline Updates 95
Hyperlipidemia - Dormant Projects 111
Hyperlipidemia - Discontinued Products 117
Hyperlipidemia - Product Development Milestones 118
Featured News & Press Releases 118
Sep 01, 2015: Cholesterol-Lowering Treatment Repatha (Evolocumab) Offers New Way To Help UK Patients 118
Jul 28, 2015: Catabasis Pharmaceuticals Will Present the CAT-2000 Program of SREBP Modulators for Hyperlipidemias at the Kern Lipid Conference 119
Jul 27, 2015: Catabasis Pharmaceuticals and UT Southwestern Medical Center Enter into a Sponsored Research Agreement for CAT-2000 Series in Serious Lipid Disorders 119
Mar 23, 2015: Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx 120
Nov 18, 2014: Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 121
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 122
Mar 19, 2014: Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia 125
Apr 13, 2012: HanAll BioPharma Initiates Phase I And III Trials Of HL040 126
Mar 19, 2010: FDA warns about increased risk of muscle injury with Zocor. 126
Mar 27, 2003: Zocor selected as sole high-potency HMG agent for U.S. Department of Veteran Affairs and Department of Defense. 126
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List Of Tables
Number of Products under Development for Hyperlipidemia, H2 2015 11
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Comparative Analysis by Unknown Stage Development, H2 2015 19
Products under Development by Companies, H2 2015 20
Products under Development by Companies, H2 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2015 22
Hyperlipidemia - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2015 23
Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 24
Hyperlipidemia - Pipeline by Amgen Inc., H2 2015 25
Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2015 26
Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015 27
Hyperlipidemia - Pipeline by CJ CheilJedang Corp., H2 2015 28
Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 29
Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 30
Hyperlipidemia - Pipeline by Huons Co., Ltd., H2 2015 31
Hyperlipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015 32
Hyperlipidemia - Pipeline by Innovent Biologics, Inc., H2 2015 33
Hyperlipidemia - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 34
Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 35
Hyperlipidemia - Pipeline by LG Life Sciences, Ltd., H2 2015 36
Hyperlipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2015 37
Hyperlipidemia - Pipeline by Pfizer Inc., H2 2015 38
Hyperlipidemia - Pipeline by Pharmena SA, H2 2015 39
Hyperlipidemia - Pipeline by Prometheon Pharma, LLC, H2 2015 40
Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2015 41
Hyperlipidemia - Pipeline by TSH Biopharm Corporation Limited, H2 2015 42
Hyperlipidemia - Pipeline by Yuhan Corporation, H2 2015 43
Assessment by Monotherapy Products, H2 2015 44
Assessment by Combination Products, H2 2015 45
Number of Products by Stage and Target, H2 2015 47
Number of Products by Stage and Mechanism of Action, H2 2015 49
Number of Products by Stage and Route of Administration, H2 2015 51
Number of Products by Stage and Molecule Type, H2 2015 53
Hyperlipidemia Therapeutics - Recent Pipeline Updates, H2 2015 95
Hyperlipidemia - Dormant Projects, H2 2015 111
Hyperlipidemia - Dormant Projects (Contd..1), H2 2015 112
Hyperlipidemia - Dormant Projects (Contd..2), H2 2015 113
Hyperlipidemia - Dormant Projects (Contd..3), H2 2015 114
Hyperlipidemia - Dormant Projects (Contd..4), H2 2015 115
Hyperlipidemia - Dormant Projects (Contd..5), H2 2015 116
Hyperlipidemia - Discontinued Products, H2 2015 117

List Of Figures
List of Figures
Number of Products under Development for Hyperlipidemia, H2 2015 11
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Products, H2 2015 18
Assessment by Monotherapy Products, H2 2015 44
Assessment by Combination Products, H2 2015 45
Number of Products by Top 10 Targets, H2 2015 46
Number of Products by Stage and Top 10 Targets, H2 2015 46
Number of Products by Top 10 Mechanism of Actions, H2 2015 48
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 48
Number of Products by Top 10 Routes of Administration, H2 2015 50
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 50
Number of Products by Top 10 Molecule Types, H2 2015 52
Number of Products by Stage and Top 10 Molecule Types, H2 2015 52
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 

Related Reports

REQUEST SAMPLE    ASK FOR DISCOUNT